Knowledge of medications and understanding of Mexican patients regarding the non-medical switch from originator to its biosimilar in inflammatory arthritis

Q3 Health Professions

Revista Colombiana de Reumatologia Pub Date : 2025-04-01 DOI:10.1016/j.rcreu.2023.12.007

Carlos Andrés Díaz-Garza , Alejandro Garza-Alpirez , David Vega-Morales , Deshiré Alpizar-Rodríguez , Berenice Carrillo-Haro

{"title":"Knowledge of medications and understanding of Mexican patients regarding the non-medical switch from originator to its biosimilar in inflammatory arthritis","authors":"Carlos Andrés Díaz-Garza , Alejandro Garza-Alpirez , David Vega-Morales , Deshiré Alpizar-Rodríguez , Berenice Carrillo-Haro","doi":"10.1016/j.rcreu.2023.12.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction/Objective</h3><div>Our aim was to know patient's understanding and concerns about biosimilars, switching, and non-medical switch in Mexican population.</div></div><div><h3>Materials and methods</h3><div>A cross-sectional social media survey via the Mexican Foundation for Rheumatic Patients (FUMERAC) was conducted from November 2020 to January 2021. Patients were eligible if they were >18 years of age with any inflammatory rheumatic condition.</div></div><div><h3>Results</h3><div>A total of 165 participants completed the survey. The most frequent diagnoses were Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis. Disease-modifying antirheumatic drugs as monotherapy was the most common treatment. Prior or current users of biologics were reported. Most participants had never heard the term biosimilar<span>. Some would accept the change from an originator to its biosimilar and few would take legal measure or file a complaint if a non-medical switch were to happen. Patients had concerns on treatment effectiveness, adverse effects, reason for change, treatment duration, and other patient's experience.</span></div></div><div><h3>Conclusion</h3><div>In Mexico, the concept of biosimilars is barely known. Most patients would not take any measure if they were changed from an originator to its biosimilar.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages 105-109"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Colombiana de Reumatologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0121812324000069","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Health Professions","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction/Objective

Our aim was to know patient's understanding and concerns about biosimilars, switching, and non-medical switch in Mexican population.

Materials and methods

A cross-sectional social media survey via the Mexican Foundation for Rheumatic Patients (FUMERAC) was conducted from November 2020 to January 2021. Patients were eligible if they were >18 years of age with any inflammatory rheumatic condition.

Results

A total of 165 participants completed the survey. The most frequent diagnoses were Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis. Disease-modifying antirheumatic drugs as monotherapy was the most common treatment. Prior or current users of biologics were reported. Most participants had never heard the term biosimilar. Some would accept the change from an originator to its biosimilar and few would take legal measure or file a complaint if a non-medical switch were to happen. Patients had concerns on treatment effectiveness, adverse effects, reason for change, treatment duration, and other patient's experience.

Conclusion

In Mexico, the concept of biosimilars is barely known. Most patients would not take any measure if they were changed from an originator to its biosimilar.

查看原文本刊更多论文

墨西哥患者对药物的了解以及对炎症性关节炎患者从原研药转用生物仿制药的非医学理解

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista Colombiana de Reumatologia Medicine-Rheumatology

CiteScore

0.80

自引率

0.00%

发文量

期刊介绍： The Colombian Journal of Rheumatology (Revista Colombiana de Reumatología) is the official organ of the Colombian Association of Rheumatology (Asociación Colombiana de Reumatología) and the Central American, Caribbean and Andean Association of Rheumatology (Asociación Centroamericana Caribe Andina de Reumatología) - ACCA. It was created in December 1993 with the purpose of disseminating scientific information derived from primary and secondary research and presenting cases coming from the practice of Rheumatology in Latin America. Since its foundation, the Journal has been characterized by its plurality with subjects of all rheumatic and osteomuscular pathologies, in the form of original articles, historical articles, economic evaluations, and articles of reflection and education in Medicine. It covers an extensive area of topics ranging from the broad spectrum of the clinical aspects of rheumatology and related areas in autoimmunity (both in pediatric and adult pathologies), to aspects of basic sciences. It is an academic tool for the different members of the academic and scientific community at their different levels of training, from undergraduate to post-doctoral degrees, managing to integrate all actors inter and trans disciplinarily. It is intended for rheumatologists, general internists, specialists in related areas, and general practitioners in the country and abroad. It has become an important space in the work of all rheumatologists from Central and South America.